GLPwatch
Papers (9189)
Page 108 of 154, ranked by citation count.
- Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic Registry.
- Influence of Trp-Cage on the Function and Stability of GLP-1R Agonist Exenatide Derivatives.
- Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats.
- A novel antihypertensive effect of exenatide, a GLP-1 agonist.
- Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
- Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.
- Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
- Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.
- Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.
- Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
- Exenatide induced acute kidney injury.
- Therapy for NASH.
- Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes.
- As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes.
- Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
- Exenatide increases CTRP3 gene expression in adipose cells by inhibiting adipogenesis and induces apoptosis.
- Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database.
- Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance.
- Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
- Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real-world, population-based cohort study.
- Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
- Efficacy of liraglutide in a patient with type 2 diabetes and cryptogenic cirrhosis.
- Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.
- Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population.
- Novel neural pathways targeted by GLP-1R agonists and bariatric surgery.
- Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.
- Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model.
- Subcutaneous Semaglutide Use for Weight Management: Practice and Attitudes of Physicians in Israel.
- Weighing your options-intragastric balloon versus semaglutide.
- Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
- Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach.
- Semaglutide and Cardiovascular Outcomes.
- White analytical insight for sensitive fluorescent determination of semaglutide and tirzepatide in pharmaceuticals and biological matrices.
- Semaglutide Improves Heart Failure and Cardiovascular Disease.
- The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.
- Can Semaglutide offer hope for patients with obesity-related heart failure?
- Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Exenatide once weekly in type 2 diabetes mellitus.
- Clinical Efficacy of Once-weekly Glucagonlike Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
- Semaglutide is safe and efficacious for NASH resolution.
- Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.
- Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
- Epidermal insulin resistance as a therapeutic target in acanthosis nigricans?
- Poly(l-threonine-<i>co</i>-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide.
- Semaglutide (Ozempic) for Type 2 Diabetes Mellitus.
- Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
- Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.
- The impact of semaglutide on fusion rates following posterior lumbar fusion surgery in patients with type 2 diabetes.
- The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes.
- Do interactions between protein and phospholipids influence the release behavior from lipid-based exenatide depot systems?
- Exendin-4 differentially modulates essential functions of human dermal fibroblasts under normoglycemic and hyperglycemic conditions.
- A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.
- Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.
- Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.
- Semaglutide administration protects cardiomyocytes in db/db mice via energetic improvement and mitochondrial quality control.
- Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map.
- Use of semaglutide in a 54-year-old patient with cocaine abuse and weight loss: a case report.
- Anorgasmia following initiation of GLP-1 agonist.
- Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
- Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial.